Stock Events

Stock Events

Clearside Biomedical 

€2.98
0
+€0+0% Monday 14:33

Statistics

Day High
2.98
Day Low
2.98
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

5MarExpected
Q2 2025
Q3 2025
Q4 2025
-14.71
-9.98
-5.25
-0.52
Expected EPS
-0.517182
Actual EPS
N/A

Financials

-2,095.46%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
1.52MRevenue
-31.95MNet Income

Analyst Ratings

0Average Price Target
The highest estimate is 0.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLM0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
EyePoint
EYPT
Mkt Cap1.13B
EyePoint Pharmaceuticals focuses on developing treatments for eye diseases, directly competing with Clearside's ocular therapies.
Bausch Health Companies
BHC
Mkt Cap2.1B
Bausch Health Companies, through its eye health division, competes in developing treatments for various eye conditions.
Novartis
NVS
Mkt Cap280.79B
Novartis offers a broad portfolio of drugs, including treatments for eye diseases, competing on a global scale.
Regenxbio
RGNX
Mkt Cap452.17M
REGENXBIO's focus on AAV gene therapies for retinal diseases puts it in direct competition with Clearside's eye disease treatments.
Ocular Therapeutix
OCUL
Mkt Cap2.07B
Ocular Therapeutix develops innovative therapies for eye diseases, competing in the ocular drug delivery space.
GSK
GSK
Mkt Cap108.66B
GlaxoSmithKline, with its broad pharmaceutical portfolio, includes treatments for eye conditions, making it a competitor in the broader pharmaceutical market.

About

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Show more...
CEO
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
Employees
32
Country
United States
ISIN
US1850632035
WKN
000A41GPR

Listings

MU
DE
CLM0.MU
STU
DE
CLM0.STU
OTC Link
US
CLSDQ

0 Comments

Share your thoughts

FAQ

What is Clearside Biomedical stock price today?▼
The current price of CLM0.F is €2.98 EUR — it has increased by +0% in the past 24 hours. Watch Clearside Biomedical stock price performance more closely on the chart.
What is Clearside Biomedical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Clearside Biomedical stocks are traded under the ticker CLM0.F.
What is Clearside Biomedical revenue for the last year?▼
Clearside Biomedical revenue for the last year amounts to 1.52M EUR.
What is Clearside Biomedical net income for the last year?▼
CLM0.F net income for the last year is -31.95M EUR.
How many employees does Clearside Biomedical have?▼
As of April 29, 2026, the company has 32 employees.
In which sector is Clearside Biomedical located?▼
Clearside Biomedical operates in the Health & Wellness sector.
When did Clearside Biomedical complete a stock split?▼
The last stock split for Clearside Biomedical was on September 15, 2025 with a ratio of 1:15.
Where is Clearside Biomedical headquartered?▼
Clearside Biomedical is headquartered in Alpharetta, United States.